

NASDAQ: TECH

biotechne®

LEERINK Partners 5th Annual
Global Healthcare Conference
10 February 2016

Disclaimer

Cautionary Statements

This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies and other matters. Such statements can be identified by words such as: “expected,” “expects,” “expect,” “forecast,” “would,” “estimate,” “will,” or similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise.

This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company’s financial reports on Forms 10-Q and 10-K and related press releases.

Current Business Overview

Fiscal Year Ends: June 30
FY 2015 Revenues: \$452 MM
FY 2015 Adj. Gross Margin: 71.6%
FY 2015 Adj. Earnings: \$127 MM
FY 2015 Adjusted EPS: \$3.40
Current Market Cap: ~\$3.5B

Minneapolis,
MN HQ

1400+
Employees

Offices in
North America,
Europe, Japan
and China

Global Footprint

Extensive product
portfolio of Life Science
reagents

Extensive applications
expertise

Cytokines/GF

Immunoassays

Small Molecules

Protein Analysis
Instruments

Automated
Immunoassay
Platform

Clinical Chemistry,
Controls and Calibrators

Products

Cliniqa

ProteinSimple

Novus
Biologicals


CyVek

PrimeGene

Bionostics

Recent Acquisitions

Organic Sales Growth^{1,2}



¹Organic sales figures exclude the impact of acquisitions and foreign currency exchange rates

²Geographic growth only represents Biotechnology segment

Large Addressable Market Opportunities



Customers Served

- Pharma
- Biotech
- Academia
- CROs
- Hospitals
- Foundations
- Government

Current Reportable Segments



Biotechnology

- Legacy R&D Systems
- PrimeGene
- Novus




Clinical Controls

- Legacy R&D Systems
- Cliniqa
- Bionostics




Protein Platforms

- ProteinSimple
- Simple Plex



Note: All margin percentages have been adjusted to exclude impact of acquisition costs

Strategic Plan



biotechne®



275,000
products

1400
employees

39
years

330,000
citations

Instruments



Together our brands bring you >275,000 quality products

Over 1400 employees globally

Bio-Techne brands have been manufacturing and sourcing reagents for 39 years

>330,000 citations have been generated using our products

4 Instrument platforms that leverage biological content